404 Phase I study of MEDI-575, a fully human monoclonal antibody targeting PDGFR-alpha in subjects with advanced solid tumors

European Journal of Cancer Supplements ◽

10.1016/s1359-6349(10)72111-x ◽

2010 ◽

Vol 8 (7) ◽

pp. 128 ◽

Author(s):

R. Lechleider ◽

C. Becerra ◽

M. Liang ◽

R. Narwal ◽

L. Shi ◽

...

Keyword(s):

Monoclonal Antibody ◽

Phase I ◽

Solid Tumors ◽

Phase I Study ◽

Human Monoclonal Antibody ◽

Advanced Solid Tumors ◽

Antibody Targeting ◽

Download Full-text

Phase I Study of U3-1287, A Human Monoclonal Antibody Targeting Her3, in Japanese Patients with Advanced Solid Tumors

Annals of Oncology ◽

10.1016/s0923-7534(20)33026-x ◽

2012 ◽

Vol 23 ◽

pp. ix161-ix162

Author(s):

H. Wakui ◽

N. Yamamoto ◽

S. Nakamichi ◽

Y. Tamura ◽

H. Nokihara ◽

...

Keyword(s):

Monoclonal Antibody ◽

Phase I ◽

Solid Tumors ◽

Phase I Study ◽

Human Monoclonal Antibody ◽

Japanese Patients ◽

Advanced Solid Tumors ◽

Antibody Targeting

Download Full-text

Abstract C18: A phase I study of enavatuzumab (PDL192, ABT-361), a first-in-class human monoclonal antibody targeting TWEAK (tumor necrosis factor-like inducer of apoptosis) receptor, in patients (Pts) with advanced solid tumors.

10.1158/1535-7163.targ-11-c18 ◽

2011 ◽

Author(s):

Elaine T. Lam ◽

S. Gail Eckhardt ◽

Wells Messersmith ◽

Antonio Jimeno ◽

Cindy L. O'Bryant ◽

...

Keyword(s):

Monoclonal Antibody ◽

Tumor Necrosis Factor ◽

Phase I ◽

Solid Tumors ◽

Phase I Study ◽

Tumor Necrosis ◽

Human Monoclonal Antibody ◽

Advanced Solid Tumors ◽

Antibody Targeting ◽

Necrosis Factor

Download Full-text

A phase I study of CS-1008 (humanized monoclonal antibody targeting death receptor 5 or DR5), administered weekly to patients with advanced solid tumors or lymphomas

Journal of Clinical Oncology ◽

10.1200/jco.2008.26.15_suppl.3537 ◽

2008 ◽

Vol 26 (15_suppl) ◽

pp. 3537-3537 ◽

Author(s):

M. N. Saleh ◽

I. Percent ◽

T. E. Wood ◽

J. Posey ◽

J. Shah ◽

...

Keyword(s):

Monoclonal Antibody ◽

Phase I ◽

Solid Tumors ◽

Phase I Study ◽

Death Receptor ◽

Advanced Solid Tumors ◽

Death Receptor 5 ◽

Humanized Monoclonal Antibody ◽

Antibody Targeting

Download Full-text

A first-in-human phase I study to evaluate the fully human monoclonal antibody MNRP1685A (anti-NRP1) administered intravenously every three weeks in patients with advanced solid tumors.

Journal of Clinical Oncology ◽

10.1200/jco.2010.28.15_suppl.3014 ◽

2010 ◽

Vol 28 (15_suppl) ◽

pp. 3014-3014 ◽

Author(s):

C. D. Weekes ◽

P. Hegde ◽

Y. Xin ◽

R. Yu ◽

H. Xiang ◽

...

Keyword(s):

Monoclonal Antibody ◽

Phase I ◽

Solid Tumors ◽

Phase I Study ◽

Human Monoclonal Antibody ◽

Advanced Solid Tumors

Download Full-text

Phase I Study of Enavatuzumab, a First-in-Class Humanized Monoclonal Antibody Targeting the TWEAK Receptor, in Patients with Advanced Solid Tumors

Molecular Cancer Therapeutics ◽

10.1158/1535-7163.mct-17-0330 ◽

2017 ◽

Vol 17 (1) ◽

pp. 215-221 ◽

Author(s):

Elaine T. Lam ◽

S. Gail Eckhardt ◽

Wells Messersmith ◽

Antonio Jimeno ◽

Cindy L. O'Bryant ◽

...

Keyword(s):

Monoclonal Antibody ◽

Phase I ◽

Solid Tumors ◽

Phase I Study ◽

Advanced Solid Tumors ◽

Humanized Monoclonal Antibody ◽

Antibody Targeting

Download Full-text

A Phase I Study of Weekly R1507, A Human Monoclonal Antibody Insulin-like Growth Factor-I Receptor Antagonist, in Patients with Advanced Solid Tumors

Clinical Cancer Research ◽

10.1158/1078-0432.ccr-09-3220 ◽

2010 ◽

Vol 16 (8) ◽

pp. 2458-2465 ◽

Author(s):

Razelle Kurzrock ◽

Amita Patnaik ◽

Joseph Aisner ◽

Terri Warren ◽

Stephen Leong ◽

...

Keyword(s):

Monoclonal Antibody ◽

Growth Factor ◽

Phase I ◽

Receptor Antagonist ◽

Solid Tumors ◽

Phase I Study ◽

Human Monoclonal Antibody ◽

Advanced Solid Tumors ◽

Insulin Like Growth Factor ◽

Download Full-text

Abstract B123: A phase I study of R1507, a human monoclonal antibody IGF‐1R (insulin‐like growth factor receptor) antagonist in patients with advanced solid tumors

10.1158/1535-7163.targ-09-b123 ◽

2009 ◽

Author(s):

Lia Gore ◽

Joseph Aisner ◽

Razelle Kurzrock ◽

Cinara D. McCarthy ◽

Erica Winter ◽

...

Keyword(s):

Monoclonal Antibody ◽

Growth Factor ◽

Phase I ◽

Receptor Antagonist ◽

Solid Tumors ◽

Phase I Study ◽

Human Monoclonal Antibody ◽

Growth Factor Receptor ◽

Advanced Solid Tumors ◽

Insulin Like Growth Factor

Download Full-text

Phase I and Dose Finding Study of U3-1287, a Human Monoclonal Antibody Targeting HER3, in Japanese Patients with Advanced Solid Tumors

Annals of Oncology ◽

10.1016/s0923-7534(20)32302-4 ◽

2012 ◽

Vol 23 ◽

pp. xi112

Author(s):

H. Wakui ◽

N. Yamamoto ◽

S. Nakamichi ◽

Y. Tamura ◽

H. Nokihara ◽

...

Keyword(s):

Monoclonal Antibody ◽

Phase I ◽

Solid Tumors ◽

Human Monoclonal Antibody ◽

Japanese Patients ◽

Dose Finding ◽

Advanced Solid Tumors ◽

Finding Study ◽

Dose Finding Study ◽

Antibody Targeting

Download Full-text

28 A First-in-human Phase I Study to Evaluate the Fully Human Monoclonal Antibody OMP-59R5 (anti-Notch2/3) Administered Intravenously to Patients with Advanced Solid Tumors

European Journal of Cancer ◽

10.1016/s0959-8049(12)71827-0 ◽

2012 ◽

Vol 48 ◽

pp. 11-12 ◽

Author(s):

D.C. Smith ◽

R. Chugh ◽

A. Patnaik ◽

K. Papadopoulos ◽

G. Chambers ◽

...

Keyword(s):

Monoclonal Antibody ◽

Phase I ◽

Solid Tumors ◽

Phase I Study ◽

Human Monoclonal Antibody ◽

Advanced Solid Tumors

Download Full-text

Phase I study of every 2- or 3-week dosing of ramucirumab, a human immunoglobulin G1 monoclonal antibody targeting the vascular endothelial growth factor receptor-2 in patients with advanced solid tumors

Annals of Oncology ◽

10.1093/annonc/mdv144 ◽

2015 ◽

Vol 26 (6) ◽

pp. 1230-1237 ◽

Author(s):

E.G. Chiorean ◽

H.I. Hurwitz ◽

R.B. Cohen ◽

J.D. Schwartz ◽

R.P. Dalal ◽

...

Keyword(s):

Monoclonal Antibody ◽

Vascular Endothelial Growth Factor ◽

Growth Factor ◽

Phase I ◽

Solid Tumors ◽

Phase I Study ◽

Growth Factor Receptor ◽

Vascular Endothelial ◽

Advanced Solid Tumors ◽

Endothelial Growth Factor

Download Full-text